معرفی
Andrew Hantel, M.D. serves as an Assistant Professor of Medicine at Dana-Farber Cancer Institute. His academic appointments and research activities position him at the intersection of oncology, medical ethics, and health equity.
Dr. Hantel's research interests span several critical areas in modern medicine, with particular focus on medical ethics, hematology/oncology, population sciences, and health equity. His work addresses pressing issues including climate change impacts on healthcare delivery, clinical trial diversity, and the Duffy null phenotype's implications for cancer care. He has developed innovative approaches to address healthcare disparities through multilevel interventions targeting acute leukemia clinical trial enrollment.
His publication record demonstrates expertise across multiple domains, with significant contributions to understanding how genetic variations like the Duffy null phenotype affect clinical care and trial eligibility. His work on climate-conscious medical ethics represents a growing area of scholarly interest at the intersection of environmental science and healthcare delivery.
- Equity in Access Research Grant from Leukemia and Lymphoma Society (2025-2030)
- DFCI Cancer Care Collaborative Research Award (2024-2026)
- K08CA273043-01 from NCI (2022-2027)
- Career Development Award from American Society of Clinical Oncology (2022-2025)
- Making a Difference Grant from Greenwall Foundation (2022-2024)
Dr. Hantel's educational background includes an MD from Loyola University Chicago (2013), Internal Medicine Residency and Medical Ethics Fellowship from University of Chicago (2016), Hematology/Oncology Fellowship (2019), Population Sciences Fellowship at Dana-Farber Cancer Institute (2021), and an upcoming MPH from Harvard University (2025). His academic trajectory demonstrates a commitment to integrating clinical medicine with population health perspectives and ethical considerations.
